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Summary.-The growth of a 3-methylcholanthrene-induced fibrosarcoma of C3H
mice was inhibited by aspirin and indomethacin. While the tumour contained rela-
tively high concentrations of PGE2-like material, that were markedly diminished by
indomethacin treatment, our results did not confirm the recently proposed hypo-
thesis that the anti-tumour effect arises from a restoration of depressed immune
function. For example, mice that had completely eliminated their tumours under
indomethacin administration were not immune to rechallenge. The tumour-bearing
animals were not non-specifically immunodepressed, as their splenic PFC responses
against SRBC were enhanced. However, while indomethacin augmented the PFC
response in normal mice, this adjuvant effect was depressed in tumour-bearing
animals. The spleen-cell PHA responses of tumour bearers were severely depressed,
and such cells suppressed the PHA response of normal cells. Only after prolonged
indomethacin treatment did animals (with comparable tumour burdens) show weak
PHA responses and somewhat diminished suppressive activity.
Possible alternative mechanisms, such as direct cytotoxicity, or inhibition of
inflammation, phosphodiesterase activity, blood coagulation or calcium availability
were not implicated (nor definitively excluded) in the anti-tumour effect.
TUMOUR growth in a number of experi-
mental models is inhibited by non-steroid
anti-inflammatory drugs such as aspirin
and indomethacin (Strausser & Humes,
1975; Plescia et al., 1975; Hial et al., 1976).
An immunological mechanism for this
activity has been suggested on the basis
of a series of observations, including the
inhibition of prostaglandin synthesis by
these drugs (Lewis, 1977) the high prosta-
glandin concentrations in many tumours
(Strausser & Humes, 1975; Bennett et
al., 1977; Sykes & Maddox, 1972) the
immunological unresponsiveness of some
tumour-bearing animals and immune "re-
storation" by indomethacin treatment
(Plescia et al., 1975; Strausser & Humes,
1975; Pelus & Strausser, 1976) possibly
via effects on "suppressor" cells (Goodwin
et al., 1977; Webb & Jamieson, 1976).
We have examined a 3-methylcholan-
threne-induced transplantable fibro-
sarcoma of C3H mice (McC3-1) whose
growth is also inhibited by indomethacin
(Lynch & Salomon, in press J. Natl Cancer
Inst.).
MATERIALS AND METHODS
Anirnals.-Male and female C3H/uip mice,
6 to 8 weeks old, were obtained from the
breeding facilities of the IRSC, where they
originally derived from C3H/HeJ stocks.
Tumoiirs.-Fibrosarcomas induced in C3H
mice by the i.m. injection of 1 mg 3-methyl-
cholanthrene were maintained by serial
isogeneic transplantation and freezing of
various passages. The McC3-I fibrosarcoma
was used betweeii its 10th and 14th passages.
Tumour grafts were performed ventrally by
the s.c. introductionofsmallpieces (- 1 mm3)
of non-necrotic tumour via a trocar needle.
In one series of experiments, different num-
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prepared by mechanical disaggregation of the
tumours were injected s.c. and in another
series the tumour was grafted i.m. The day
of grafting was taken as Day 0 in all experi-
ments.
Drug treaitment.-Indomethacin (Sigma)
stored at - 15°C as 10 mg/ml stocks in
absolute ethanol was diluted 1/500 for
administration in the drinking water (20 pug/
ml) which was changed 2 or 3 times per week.
Mice drank between 4 and 6 ml per day
(80 to 120 jug) and tolerated this dose for
periods of at least 3 months without evident
ill effects. In most experiments administra-
tion of the drug was begun when the tumour
became palpable (about Day 7). I.p. admini-
stration was performed by the injection of
0-1 or 0-2 ml of a 1/20 dilution of the stock in
phosphate-buffered saline (PBS). The alcohol
vehicle was used as the control for both
routes, and found to have no significant
effect on tumour growth (tumour diameters
of 16 3 ± 3-0 mm, compared to 16-6 ± 2-8
mm at Day 34 for oral administration and
19-6 + 3-9 mm for i.p. alcohol-PBS vs 20-1 i
3-5 mm for i.p. PBS).
Aspirin (lysinate, EGIC Amilly, France)
theophylline (Bruneau, Paris) hydrocortisone
(hemisuccinate, Roussel, Paris) and heparin
(sodium, 120 u/mg, Choay, Paris), were used
at the doses indicated in the Results section.
In vitro techniques.-Spleen-cell suspen-
sions from groups of 5 mice were prepared in
RPMI 1640 (Eurobio, Paris) supplemented
with 2mM glutamine (Gibco, Grand Island,
U.S.A.) and containing500 freshhuman AB or
10% foetal calf serum (decomplemented by
heating at 56°C for 30 min), 100 u/ml peni-
cillin and 100 ,ug/ml streptomycin. From
2-5 to 7.5 x 105 cells were placed in wells of
Falcon 3040 microplates (Oxnard, U.S.A.) and
a dose of Phytohaemagglutinin A (PHA,
HA16, Wellcome, Beckenham, England)
that had previously been shown to be
optimal (0-4-1.0 ,ug/well) added. All cultures
were in triplicate. The plates were incubated
at 37°C under 500 Co2 plus 950 air, for 48 h,
after which 1 ,uCi of 3H-thymidine (H3TdR;
TMM 48, Commisariat 'a l'Energie Atomique,
Gif sur Yvette, France, sp. act. 27 Ci/mM)
was added to each well for 6 h. Cultures were
harvested with a multiple automated sample
harvester ('MASH" Microbiological Asso-
ciates, Bethesda, U.S.A.) and the radio-
activity was counted in an Intertechnique
counter. The results are expressed as mean
et/min of triplicate samples + s.d.
Mouse embryo fibroblasts (MEF) pre-
pared by trypsinization (0-100, 30-60 min,
37°C) of12-day-old C3H embryos, and McC3-I
cells were grown in the above medium, using
Falcon 3013 plastic flasks and weekly
subculture. Their [3H]TdR incorporation was
tested as described above, except that 50 ,ul
of OO1M EDTA was added to each well
30 min before lharvest, after 4 days of
culture.
For all experiments in which the effects of
indomethacin or culture supernatants were
tested, 50 y1 of culture fluid was replaced by
the test solution at the beginning of culture.
The alcohol vehicle of indomethacin had no
effect upon the PHA response at the highest
concentration used (0-001%; 123,692 +
21,320 ct/mmin compared to 131,420 ± 19,600
ct/min).
Plaque fornming cell (PFC) response. The
direct Jerne technique was employed, using
a basal agarose (Labosi, Paris) layer of 1-20/0
and an upper layer of 0.6% in Eagles MEM
(Eurobio, Paris) containing 100 sheep red
blood cells (SRBC) and,-, 106 spleen cells.
After 2 h incubation at 37°C of triplicate
dishes, 1000 absorbed guinea-pig serum was
added, and incubation continued for a
further 45 min. The mice were immunized
with 0-2 ml ofa 10% SRBC suspension 5 days
before the test.
Prostaglandin assay.-Freshly collected
tissues were weighed, homogenized (Ultra-
Turrax, 2 min, ice bath) in PBS, centrifuged
(8000 g, 15 min) and then assayed by one of
us (M.A.) on superfused rat fundic strips.
Three strips in series, under 2 g tension,
were attached to an isotonic myograph and
superfused (Na 138, K 2, Ca 3 5, Mg 1P5, Cl
107, CH3COO 38 and glucose 5-5 mEq/l, pH
7-2) at 5 ml/min, 37°C. Inhibitors of as and :
adrenergic, cholinergic, histamine and sero-
tonin activities were included in the super-
fusion fluid and control assays were performed
on preparations with different pharmacologic
sensitivities (rat colon and guinea-pig ileum)
in order to verify the absence of PGF2ax,
bradykinin, angiotensin II, and P substance.
Dose-responsecurvesto PGE2 wereperformed
and the test samples assayed, at intervals of
15-20 min. The assay thus quantitated the
PGE2-like" activity, and has been found to
have a 1-01 ± 0 04 correlation with radio-
immunoassay of solvent-extracted prepara-
tions (M.A. unpublished) and the presence of
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PGE2 verified by silica-gel thin-layer chroma-
tography using chloroform:methanol: acetic
acid (18: 1: 1) as the developing solvent.
Statistics.-For normally distributed popu-
lations, mean i s.d. are presented and com-
pared by Student's t test. In other cases the
mean and range are presented and the non-
parametric Mann-Whitney U test used. The
exact factorial x2 test was used to compare
proportions of small populations.
RESULTS
Effects of various drugs on tumour growth
The effect of aspirin and indomethacin
on McC3-I tumour growth in C3H mice
was compared with other drugs with
activities like those expected from these
2 agents: anti-inflammation (hydro-
cortisone) inhibition of phosphodi-
esterase (theophylline) or anti-coagulation
(heparin). In Table I (Exp.1) it can be
seen that when continually administered
in the drinking water from Days 7 to 49,
indomethacin (20 ,ug/ml) reduced the mean
tumour diameter at Day 46 by 510% and
aspirin (1 mg/ml)causeda 420 diminution,
relative to the controls. No statistically
significant effect on tumour diameter was
observed with oral theophylline (200 ,g/
ml) or hydrocortisone (10 ,tg/ml orally
plus 200 jug s.c. twice weekly). Whilst the
proportion of animals eliminating their
tumours in any of these groups was not
significantly different from the control,
spontaneous regression of untreated
tumours was never seen. Also, the mean
survival time of the animals that died was
significantly prolonged in the hydro-
cortisone group, as it was for those
receiving indomethacin or aspirin (Exp. 1).
It should be noted that the tumour
diameters were measured, anddrugadmini-
stration halted, when the majority of the
animals in the control group had died.
Exp. 2 (Table I) presents an example
of the less commonly observed effect of
oral indomethacin (4/17 experiments),
where tumour growth commenced, but
was followed by complete and lasting
regression in most of the animals. In this
experiment no effects were observed with
theophylline (40 tg i.p. twice weekly) or
heparin injected either intra- and peri-
tumourally (i.t. + p.t., 10 u, twice weekly)
or i.p. (50 u, 3 times weekly) from Days
8 to 42.
Fig. 1 demonstrates that the regular
i.p. injection of indomethacin (100 ,g,
3 times weekly) significantly reduced the
tumour weights (P < 0 001) and spleno-
megally (P = 0032) at Day 29.
TABLE I.-Effect of various drugs on McC3-I growth
Exp. Treatment
1 Control
Indomethacin
Aspirin
Theophylline
Hydrocortisone
2 Control
Indomethacin
Theophylline
Heparin i t. +p.t.
l.p.
Tumour diam. (mm)
16 -4*
6-27
8-1 P=0-011
2-13
9-5 P=0-042
0-19
13-0 NS
0-24
12-4 NS
6-9
15-3±3 -8t
0 841 3 P<0-001
16-5±6-5 NS
18-7±4-5 NS
14 5±-1- 0 NS
Survivai
Proportion Days§
0/9 51*
46-68
2/9 64
59-70
1/9 61
49-71
1/10 52
34-70
0/8 60
47-69
0/8 42 +-4t
4/5 63
0/8 43±5
0/8 40--7
0/6 37-' 9
* Mean and range
t Mean ± s.d.
t Significance of 4/5 survivors
§ survival time of those dying
P=0 004
P=0-027
NS
P=0-014
P=0 014T
NS
NS
NS
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FIG. 1.-Control (0*) and indomethacin-
treated (0) mice. The mean ± s.d. is also
shown.
Effect of indomethacin on McC3-I in vitro
McC3-I cells in their 1st to 4th in vitro
passages were grown in media containing
0-1 to 20 ,ug/ml indomethacin. Starting
cell concentrations of 4 x 103 to 105 cells/
well were used, and the incorporation of
TABLE II.-Mean±s.d. (ny/mg) PGE2-like
activity in mouse tissues
Muscle Liver Spleen Tumour
Normal C3H <0*025 <0*050 0*234
±0*042
Indo. treated <0-025 <0 050 0.075
±0006
Tumour- 0*019 0*025 0* 186 0*590
bearing C3H ±0-008 ±0-008 ±0-008 ±0 093
Indo. treated 0*023 <0*050 0*036 0*095
±O*008 ±0°009 ±iO045
[3H]TdR during 6 h on the 4th day of
culture was measured. In all experiments,
low indomethacin concentrations had no
significant effect on cell proliferation, and
higher concentrations were weakly stimu-
latory (e.g., a control incorporation of 464
± 86 ct/min for second passage cells vs.
1169 = 285 ct/min in 20 ,ug/ml indome-
thacin; a2-5-fold stimulation, P < 0-001).
Prostaglandins and bone resorption in
tumour-bearing mice
The concentration ofPGE2-like activity
in McC3-I tumours and other tissues, and
the effect of indomethacin treatment, are
FIG. 2.-Tibia from tumour-bearing (lower right), tumour plus indomethacin (lower left) and control
(upper) mice.
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presented in Table II. The concentration
was considerably greater in the spleen and
29-day-old tumours than in other organs,
the tumours having the highest levels in
most assays. Indomethacin treatment
(100 ,tg i.p., 3 times weekly) markedly
reduced the concentrations in these tissues
(Table II).
As tumour-associated prostaglandins
have been implicated in the bone-resorbing
activity of certain tumours, we also
examined the effect of i.m. transplanted
McC3-1 on the morphology of the tibia,
and plasma calcium levels, in the presence
or absence of indomethacin. The tumour
caused substantial bone destruction, and
this was diminished by oral indomethacin
(Fig. 2). Plasma calcium levels were
significantly (P < 0 001) higher than
normal (84 0 5 6K1 mg/l vs 63-2 ± 2 4
mg/l) but were reduced by indomethacin
treatment (68.8 + 9-7 mg/l). S.c. grafted
tumours minimally (though statistically
significantly) raised plasma calcium levels
above controls (91.2 ± 1-2 vs 88 0 ± 0-8
mg/l; P < 0.02).
Immunity after tumour regression
In order to test for persistent specific
immunity against McC3-I in animals that
had completely eliminated their tumours
underindomethacin treatment, rechallenge
grafts were performed. The second graft
was given about 2 months after the first
had completely regressed, to minimize
non-specific influences that have occasion-
ally been observed at earlier times, and
when protective immunity (if present) is
still detectable (unpublished). Thus, 6
mice that had completely rejected their
primary grafts by Day 40, and remained
tumour-free after withdrawal of the indo-
methacin, were regrafted at Day 105. The
challengegraftgrewin all of these animals.
It is of interest to note that, when small
McC3-I tumours (10-15 mm diameter)
were surgically removed from untreated
C3H 20 days after grafting, challenge
grafts 50 days later grew in 8/10 cases.
Also, the injection of 109 killed C. parvum
organisms into small, growing McC3-I
tumours regularly induced the rejection of
all of these by about Day 40, with or with-
out indomethacin treatment (Lynch &
Salomon, in press J. Natl Cancer Inst.).
When such animals were regrafted 50 days
after complete elimination of theirtumours
by C. parvum treatment alone, the second
graft grew in 0/7 cases, and in 1/10 cases
after C. parvum plus indomethacin. No in-
hibition of the growth of an unrelated 3-
methylcholanthrene-induiced C3H fibro-
sarcoma (McC3-II) was observed in such
animals.
Effect of tumour- and indomethacin on
antibody synthesis
In a number of experiments the effect
of idomethacin on the spleen direct PFC
response to SRBC was examined in normal
C3H, and those bearing McC3-I tumours of
various sizes. It was found that continuous
oral indomethacin administration (20 jug/
ml) commenced before immunization, but
not simultaneously with the antigen,
strongly enhanced the total and relative
(/106 cells) spleen PFC response in normal
animals (Table III). The number of
PFC/106 spleen cells was not less than
normal, in untreated tumour-bearing mice,
even when the tumours were very large
(e.g. 3-2 ± 1.9 g at Day 30; Table III). In
TABLE III. Effect ofturmaour and indomethacin on spleen anti-SRBC direct PFC response
Treatment
Control
Indo. Day 0 to 5*
Indo. Day - 2 to 5
Tumour
Ttumour + in(lo. Day -2 to 5
Cells/spleen
x 10-8 t~s.d.
1-1±0 :3
09 90 2
1 640 4
3 - 0 + 06 6
2-6E-0\2
Total PFC/spleen
- s.d.
41700± 14300
40565± :3273
142000 19000
1445004 31000
142000- 41000
* Relative to (lay of immuinization.
PFC/1fi cells
( s.cl.
405198
476± 69
922 ± 328
48:3± 115
552-- 171
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TABLE IV. Effect of tumour and indomethacin on PHA response
[3H] TdR incorporation (ct/min -- s.d.)
Exp. Control
la* -PHA
1853
±107
lb 2334
+118
2at 30
- 7
2b 1196
- 747
± PHA
124623
27960
60969
-+ 8568
32360
± 3631
41013
+- 5622
2c 580 50338
±403 ±3825
Indomethacin
-PHA
3368
4102
3190
±418
49
+ 11
364
+-112
+ PHA
68278
±2517
45267
±998
22867
- 3419
46325
-+5458
Tumour
- PHA
2798
236
2335
-274
169
±4
538
-583
+ PHA
14358
-1896
9074
±331
1328
-183
2579
+ 192
1307 2469
4-396 71808
Tumour + Indo
-PHA + PHA
3174 18490
± 656 ± 1860
2873 10125
±184 ± 1297
126 7682
+ 36 ±877
433 11067
± 20 + 1263
3312 20586
7712 ± 1000
* Exp. la. Indomethacin in drinking water (10 ,ug/ml) and injected i.p. (50 ,ug daily) in groups of 4 mice
for 3 days before the test. McC3-I grafted 29 days before test.
b. As a, with the inclusion of 2 ,ug/ml indomethacin in all culture fluids.
t Exp. 2a. Indomethacin or control alcohol vehicle in drinking water for 40 days before test. Tumour
group grafted with 4 x 104 McC3-I cells and (tumour + indo.) group with 2 x 105 cells, 40
days before test (tumour weights 3-2 ± 1-1 g and 3-5 ± 1-4 g).
b. As a, with inclusion of 0 5 ,ig/ml idomethacin in all culture fluids.
c. Spleen cells from control, tumour-bearing or (tumour + indo.) mice added to an equal number
of normal spleen cells. Response of normal cells alone: 34,261 ± 4257.
fact, because of the splenomegaly induced
by the tumour, the total number of PFC
per spleen was considerably raised (P <
0*001). The presence of the tumour did,
however, significantly (P < 0.01) reduce
the augmentation of PFC/106 cells induced
by indomethacin treatment (Table III).
In these experiments the indomethacin
was only administered from one or 2 days
before immunization until the day of the
test, so that the size ofthe tumour was not
significantly modified.
Effect of tumour and indomethacin on PHA
response
While the spontaneous incorporation of
[3H]TdR by spleen cells from tumour-
bearing animals was generally greater
than that of equal numbers of normal
spleen cells, the PHA response of the
tumour bearers was drastically reduced
(Table IV, Exp. la). Oral and/or i.p.
administration of indomethacin, or its
addition to the in vitro culture fluids at
concentrations of 0-1-10 [kg/ml, often in-
creased the spontaneous incorporation by
normal spleen cells, and somewhat re-
duced their PHA response, without being
toxic. Short periods (4-6 days) of indo-
methacin treatment had little effect on the
PHA response ofspleen cells from tumour-
bearing animals, even when the drug was
also added in vitro (Table IV, Exp. lb).
Longer periods ofindomethacin admini-
stration (10-40 days) to tumour bearers
did not provide a valid test of the effect of
indomethacin alone, as the tumour growth
was also depressed by this treatment. In
order to compare the effect of extended
drug administration to tumour bearers,
with mice withequivalenttumourburdens,
control mice were grafted with 4 x 104
McC3-I cells, while those that were given
long term indomethacin received higher
doses of cells (2 x 105). The slower growth
of the lower cell inoculum then matched
that of the drug-treated tumours. Under
these circumstances, long-term in vivo
drug administration increased the PHA
response of tumour bearers 6-fold (Table
IV, Exp. 2a). However, even this en-
hanced response was still only 2500 of
that of control animals. The addition of
indomethacin in vitro at a low concentra-
tion slightly enhanced the effect of long-
term in vivo administration of the drug
(Table IV, Exp. 2b). Spleen cells from
animals carrying the McC3-I tumours
almost totally suppressed the PHA re-
sponse of normal spleen cells (Table IV,
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Exp. 2c) but when the tumour-bearers
were treated with indomethacin their
cells caused only a moderate suppression
of the normal response.
When supernatants from 3rd in vitro
passage McC3-1 cultures were added to
normal spleen cells, the PHA response of
these was significantly (P < 0-001) aug-
mented (Table V). This enhancing activity
TABLE V.-Effect of cultutre supernatants
on PHA response
[3H]TdR incorporation
ct/min s.(l.
-PHA
Control 286 -453 1
+ In(io 6354 169 1
±TuCSn 629±21 2
+ (TuC + IncJo.) Sn 643 299 1
+ MEF Sn 484 161 1
+ (MEF + Indo.) Sn 554±96
TuC = McC3-I cells.
Sn= supernatant.
MEF = mouse embryo fibroblasts.
PHA
l3418-t .378
14964m 1025
?3976 3502
11065 ±3649
3356±2219
9176± 357
was significantly (P < 0-001) diminished
when the supernatants were obtained
from McC3-1 cells cultured in I ,ug/ml
indomethacin. Supernatants from 3rd
passage normal mouse embryo fibroblast
cultures were not stimulatory.
DISCUSSION
We and others (Strausser & Humes,
1975; Plescia et al., 1975; Hial et al., 1976)
have found that the growth of experi-
mental tumours in vivo can be inhibited,
and the survival of the host prolonged, by
the administration ofaspirin orindometha-
cin. While these drugs may inhibit cell
metabolism in some systems (Hial et al.,
1976; 1977), their activity against McC3-1
does not appear to be due to a direct
cytotoxic or cytostatic effect, as low
indomethacin concentrations had no signi-
ficant effects on in vitro thymidine in-
corporation, and higher levels were slightly
stimulatory. Comparable effects were ob-
served by Santoro et al. (1976).
It is unlikely (Strausser & Humes,
1975) that the reduced tumour sizes
observed after the administration of
these non-steroid anti-inflammatory drugs
resulted simply from the removal of the
inflammatory component, becausesurvival
times were significantly increased and
complete elimination of McC3-I tumours
occurred in some cases. Also hydrocorti-
sone, a potent anti-inflammatory agent,
did not significantly reduce the tumour
size, although it did prolong the life ofthe
tumour bearers. This effect on survival
may have been due, however, to its
influence on activities other than the
inflammatory response per se (e.g., sup-
pressor cells, Schechter & Feldman,
1977). Also hydrocortisone, like aspirin
and indomethacin, diminishes the pro-
duction of prostaglandins (Tashjian et al.,
1975). These latter 2 drugs inhibit the
cyclo-oxygenase catalysis of the prelimi-
nary step of the prostaglandin biosynthe-
tic pathway (Lewis, 1977). The McC3-I
tumour, like many others (Strausser &
Humes, 1975; Sykes & Maddox, 1972;
Bennett et al., 1977) contains particularly
high concentrations ofprostaglandins, and
these levels are markedly diminished by
indomethacin treatment. It has been
suggested that the immunosuppression
described in some tumour-bearing animals
resultsfrom theinfluence ofthesehormones
on the immune system. Aspirin and
indomethacin may, therefore, restore the
immune function by inhibiting their syn-
thesis (Plescia et al., 1975; Strausser &
Humes, 1975; Pelus & Strausser, 1976)
and thus augmenting the anti-tumour
immune responses. This attractive hypo-
thesis is not, however, necessarily sup-
ported by our results with the McC3-I
tumour. Thus, while the in vivo growth of
the tumour was markedly diminished by
these drugs, we found no evidence of a
generalized immunosuppression in un-
treated animals. The total primary anti-
SRBC response was actually enhanced,
even (or particularly) by large tumours.
No diminution of the serum IgG, and
IgE titres against ovalbumin was observed
in such animals (Lynch & Salomon,
1977a). Like Webb & Osheroff (1976)
we found that indomethacin pretreatment
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of normal mice enhanced the anti-SRBC
response, but not when the drug was
administeredsimultaneously with, or after,
the antigen. Such an activity may, there-
fore, have little relevance to the McC3-I
system, as the drug was administered only
to animals carrying palpable tumours. It
is possible, however, that the critical
quantity of antigen required to trigger an
immune response was only attained when
the tumour reached a certain mass. We
have in fact found that indomethacin
exerted little effect on tumour growtlh
until the tumours reached diameters of
' 10 mm (Lynch & Salomon, in press J.
Natl Cancer Inst.). It should be noted that
the McC3-I tumour appears to be weakly
immunogenic in untreated animals, and
eventhose that completely eliminated their
tumours while receiving indomethacin
showed no immunity. This contrasts with
the situation where the tumours were re-
jected after i.t. C. parvum treatment, when
lasting specific anti-tumour immunity was
demonstrated. It is of interest that
indomethacin treatment did not inhibit,
but rather stimulated, the immuno-
therapeutic effect of C. parvum (Lynch &
Salomon, in press J. Natl Cancer Inst.) and
that such animals were equally immune.
As for the tumour systems described by
Pelus & Strausser (1976) and Goodwin
et al. (1977) the PHA response of lympho-
cytes from animals bearing McC3-I
tumours was markedly lower than normal.
This was not simply due to a dilution of
the mitogen-sensitive cells in the greatly
hyperplastic spleens, as such cells also
suppressed the proliferative response of
normal spleen cells. However, in contrast
to those authors, we observed little
restoration of the PHA response by short-
term in vivo or in vitro indomethacin
administration. When the experimental
design ensured comparable tumour bur-
dens, long-term drug treatment was found
to increase the P1IA response of tumour
bearers 6-fold, to attain 25%0 of the
normal level. As described in other
systems (Goodwin et al., 1977; Webb and
Jamieson, 1976) the stuppressive activity
was also diminished. It is difficult to
formulate a hypothesis explaining the
anti-tumour effect of indomethacin on
the basis of these relatively modest in-
creases in PHA response. In addition,
the responsibility of tumour-derived
(i.e. non-host) prostaglandins for the
inhibition of the PHA response seems
unlikely, considering our observation that
supernatantsfromMcC3-I culturesactually
enhancedtheproliferativeresponseofspleen
cells, and that this activity was diminished
by indomethacin treatment of the tumour
cells. Supernatants of normal mouse
embryo fibroblast culture were not stimu-
latory, and (unpublished observations)
co-cultivation of McC3-I cells with the
spleen cells also enhanced the response.
Thus, the hypothesis ofa central role for
the immune system in the anti-tumour
activityT of aspirin and indomethacin can
be questioned, at least for the McC3-I
model. Indeed, these drugs possibly in-
hibit lymphocyte-mediated cytotoxicity
(Winchurch et al., 1974). We have yet to
evaluate fully the contribution of possible
alternative mechanisms. It appears, for
example, unlikely that the effect of the
drugs is due to inhibition (Coulson et al.,
1977) of phosphodiesterase, as theophyl-
line did not alter McC3-I growth. Theo-
phylline has in fact been found to exert
anti-tumour effects in some systems (Webb
et al., 1972) but even these may result
from prostaglandin antagonism (Manku
& Horrobin, 1976). Also, whilst aspirin
and indomethacin can influence the blood-
coagulation system (e.g. by enhancing
fibrinolysis; Moroz, 1977) and thus modify
tumour growth (Hilgard & Thornes,
1976) heparin treatment was without
effect on McC3-I. It is evident, however,
that such possibilities can only be defi-
nitively excluded by more direct experi-
mentation, and the use of drugs having
similar overall effects via different mecha-
nisms. That inhibition of prostaglandin
synthesis is actually the basis of the
indomethacin effect is suggested by pre-
liminary (unpublished) experiments in
which its anti-tumour activity was signi-
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ficantly diminished by the daily i.p.
injection of 1-5 Kg PGE2, although deriva-
tives of this hormnone inhibit tumour
growth in some systems (Santoro et al.,
1976).
It may also be postulated that by
inhibiting the prostaglandin-associated
bone-resorbingactivityoftumours (Straus-
ser & Humes, 1975; Powles et al., 1976;
Atkins et al., 1977) indomethacin restricts
the calcium available to the neoplastic
cells (Strausser & Humes, 1975). How-
ever, while i.m. grafted McC3-1 tumours
caused indomethacin-inhibitable bone de-
formation identical to that previously
described (Strausser & Humes, 1975),
only these, and not s.c. grafted tumours,
produced clearly raised plasma calcium
levels that were diminished by indo-
methacin treatment.
We are currently investigating the
possibility that tumour-associated pro-
staglandins are responsible for the in-
hibition of anaphylactic-type reactions
(Lewis, 1977; Dunn et al., 1976) in tumour
bearing mice (Lynch & Salomon, 1977a).
Aspirin and indomethacin may, therefore,
augment the activity of such reactions
(Lewis, 1977) in tumour rejection (Lynch
& Salomon, 1977b).
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